VA semaglutide trial enrolls 600 veterans for 28 weeks total

The VA semaglutide trial will test whether weekly GLP-1 shots can reduce alcohol misuse among veterans across 18 medical centers.

18 VA centers join trial

The Department of Veterans Affairs said Thursday that it plans to enroll more than 600 veterans in the study. Participants will receive either injectable semaglutide, a GLP-1 medicine used for diabetes and weight management, or a placebo for 28 weeks.

Researchers will track alcohol consumption, health measures and quality of life, according to the agency. Veterans Affairs Secretary Doug Collins said, "This clinical trial reflects medical research that VA is uniquely situated to launch, and is aimed directly at benefitting veterans."

The trial gives the VA a larger test of a question that has moved faster in clinics than in addiction research: whether drugs that affect appetite and cravings can also reduce heavy drinking. Early studies suggest GLP-1 medicines may dampen urges tied to alcohol and other substances, but the evidence remains limited.

Alcohol misuse shapes veteran risk

Alcohol misuse has been a persistent health problem in the military and veteran community. The source material, citing estimates based on federal data, said about 14% of veterans abuse alcohol, compared with just under 10% of the general population.

VA research has found higher risk among men and among veterans who served in combat zones. A 2020 study from Syracuse University's Lerner Center for Public Health Promotion also linked traumatic brain injuries among veterans with a greater likelihood of excessive drinking.

The VA's study is aimed at a population where alcohol problems can overlap with injuries, stress, pain and reintegration after service. Those factors can make treatment harder because heavy drinking may be tied to several medical and social pressures at once.

GLP-1 evidence remains early

Semaglutide belongs to the GLP-1 class, which has become widely prescribed for diabetes and weight loss. The drugs can affect appetite and reward pathways, making them a candidate for addiction research, but researchers have not yet established long-term safety or effectiveness for alcohol use disorder.

The placebo-controlled design matters because reduced drinking can be influenced by counseling, monitoring, motivation and the expectations that come with joining a trial. Comparing semaglutide against placebo over 28 weeks should help researchers separate the drug's effect from those surrounding factors.

If the study finds lower alcohol consumption without major safety concerns, the VA would have evidence to consider a new treatment path for veterans who do not respond to existing options. For the wider pharmaceutical sector, positive data would intensify interest in GLP-1 drugs beyond metabolic disease and weight management.

If the trial shows weak benefit or difficult side effects, the agency would likely keep GLP-1 use closer to its established diabetes and weight roles. The broader industry effect would be narrower: addiction claims would face a higher evidence bar, and future studies would need clearer patient selection or longer follow-up.

The global macro effect from this trial alone is limited, but the mechanism could become larger if GLP-1 drugs gain evidence across addiction care. Wider use would raise questions for public health budgets, insurer coverage and drug supply, especially where demand for diabetes and weight-loss treatment is already high.

The named uncertainty is durability. Researchers still need to know whether any reduction in drinking lasts after injections stop, whether benefits differ by veteran subgroup, and whether weekly semaglutide can be combined safely with other addiction or mental health treatments.